BRPI0610322B8 - vegf receptor and hgf receptor signaling inhibitors and pharmaceutical composition - Google Patents

vegf receptor and hgf receptor signaling inhibitors and pharmaceutical composition

Info

Publication number
BRPI0610322B8
BRPI0610322B8 BRPI0610322A BRPI0610322A BRPI0610322B8 BR PI0610322 B8 BRPI0610322 B8 BR PI0610322B8 BR PI0610322 A BRPI0610322 A BR PI0610322A BR PI0610322 A BRPI0610322 A BR PI0610322A BR PI0610322 B8 BRPI0610322 B8 BR PI0610322B8
Authority
BR
Brazil
Prior art keywords
receptor signaling
hgf
pharmaceutical composition
receptor
signaling inhibitors
Prior art date
Application number
BRPI0610322A
Other languages
Portuguese (pt)
Inventor
Wahhab Amal
Vaisburg Arkadii
Raeppel Franck
Gaudette Frederic
Zhan Lijie
Isakovic Ljubomir
Granger Marie-Claude
Mannion Michael
Zhou Nancy
Bernstein Naomy
Mario Saavedra Oscar
Deziel Robert
Raeppel Stephane
William Claridge Stephen
Original Assignee
Methylgene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methylgene Inc filed Critical Methylgene Inc
Publication of BRPI0610322A2 publication Critical patent/BRPI0610322A2/en
Publication of BRPI0610322B1 publication Critical patent/BRPI0610322B1/en
Publication of BRPI0610322B8 publication Critical patent/BRPI0610322B8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

inibidores de sinalização de receptor de vegf e receptor de hgf. a presente invenção refere-se à inibição de sinalização de receptor de vegf e sinalização de receptor de hgf. a invenção fornece compostos e métodos para inibição da sinalização de receptor de vegf e sinalização de receptor de hgf. a invenção também fornece composições e métodos para tratar doenças e condições proliferativas celulares.inhibitors of vegf receptor and hgf receptor signaling. The present invention relates to the inhibition of vegf receptor signaling and hgf receptor signaling. the invention provides compounds and methods for inhibiting vegf receptor signaling and hgf receptor signaling. the invention also provides compositions and methods for treating cell proliferative diseases and conditions.

BRPI0610322A 2005-05-20 2006-05-19 vegf receptor and hgf receptor signaling inhibitors and pharmaceutical composition BRPI0610322B8 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68303605P 2005-05-20 2005-05-20
US60/683,036 2005-05-20
US75490205P 2005-12-29 2005-12-29
US60/754,902 2005-12-29
US78505406P 2006-03-22 2006-03-22
US60/785,054 2006-03-22
PCT/IB2006/004306 WO2008041053A2 (en) 2005-05-20 2006-05-19 Inhibitors of vegf receptor and hgf receptor signaling

Publications (3)

Publication Number Publication Date
BRPI0610322A2 BRPI0610322A2 (en) 2010-06-15
BRPI0610322B1 BRPI0610322B1 (en) 2020-12-01
BRPI0610322B8 true BRPI0610322B8 (en) 2021-05-25

Family

ID=39190471

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610322A BRPI0610322B8 (en) 2005-05-20 2006-05-19 vegf receptor and hgf receptor signaling inhibitors and pharmaceutical composition

Country Status (13)

Country Link
US (2) US8093264B2 (en)
EP (1) EP1957498B1 (en)
JP (1) JP5148499B2 (en)
KR (1) KR101378716B1 (en)
CN (1) CN101796055B (en)
AU (1) AU2006343808B2 (en)
BR (1) BRPI0610322B8 (en)
CA (1) CA2611370C (en)
ES (1) ES2623221T3 (en)
IL (1) IL187484A (en)
MX (1) MX2007014616A (en)
NZ (1) NZ564283A (en)
WO (1) WO2008041053A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
CN101031570B (en) * 2004-07-30 2012-09-05 梅特希尔基因公司 Inhibitors of VEGF receptor and HGF receptor signaling
NZ563774A (en) 2005-05-20 2010-04-30 Methylgene Inc Inhibitors of VEGF receptor and HGF receptor signaling
PE20070619A1 (en) * 2005-09-27 2007-07-02 Wyeth Corp I HAVE (2,3-b) PYRIDIN-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS
TW200806675A (en) * 2006-01-30 2008-02-01 Array Biopharma Inc Heterobicyclic thiophene compounds and methods of use
CA2645137A1 (en) * 2006-03-07 2007-09-13 James F. Blake Heterobicyclic pyrazole compounds and methods of use
US20080064718A1 (en) * 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity
CA2651898A1 (en) 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
US20110053931A1 (en) * 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2009026717A1 (en) * 2007-08-29 2009-03-05 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
TW200916447A (en) * 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
EP2426108B1 (en) 2007-08-29 2016-08-10 MethylGene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
US8906647B2 (en) 2008-02-21 2014-12-09 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome P450
BRPI0923670A2 (en) * 2008-03-05 2013-07-30 Methylgene Inc protein tyrosine kinase activity inhibitors and their use, as well as a composition comprising them
JP5675614B2 (en) 2008-08-26 2015-02-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Thienopyrimidine for pharmaceutical composition
EP2340244A4 (en) 2008-10-14 2012-07-25 Ning Xi Compounds and methods of use
BRPI0920765A2 (en) * 2008-10-29 2015-08-18 Deciphera Pharmaceuticals Llc Cilopropane amides and analogs that exhibit anticancer and antiproliferative activities
RU2011142597A (en) * 2009-03-21 2013-04-27 Саншайн Лейк Фарма Ко., Лтд. DERIVATIVES OF COMPOUND ETHERS OF AMINO ACIDS, THEIR SALTS AND METHODS OF APPLICATION
AU2010339444A1 (en) * 2009-12-30 2012-07-19 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
JP5575275B2 (en) 2010-02-26 2014-08-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted alkyl group-containing thienopyrimidines for pharmaceutical compositions
UY33246A (en) 2010-02-26 2011-09-30 Boehringer Ingelheim Int TIENOPIRIMIDINES CONTAINING CYCLLOQUAL FOR PHARMACEUTICAL COMPOSITIONS
UY33241A (en) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ? Tienopyrimidines containing heterocycloalkyl for pharmaceutical compositions ?.
CN101863911A (en) * 2010-04-13 2010-10-20 艾琪康医药科技（上海）有限公司 A process for preparing 1-R1-3, 4-dehydro-3 or 4-R6-piperidine
EP2563794A4 (en) * 2010-04-16 2013-12-04 Methylgene Inc Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
KR20130091331A (en) 2010-07-16 2013-08-16 교와 핫꼬 기린 가부시키가이샤 Nitrogenated aromatic heterocyclic ring derivative
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
MY181439A (en) 2011-02-28 2020-12-22 Sunshine Lake Pharma Co Ltd Substituted quinoline compounds and methods of use
CN104936963B (en) 2012-11-20 2017-11-28 普罗齐纳斯有限公司 Sulfide derivative as kinases inhibitor
AU2015249496A1 (en) 2014-04-25 2016-09-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
CN105348213A (en) * 2015-09-22 2016-02-24 武汉理工大学 Preparation method for beta-fluoroalkyl-beta-amino acids compound
FR3041640B1 (en) 2015-09-30 2019-05-17 Les Laboratoires Servier NOVEL PYRROLO [2,3-d] PYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
RU2019108280A (en) 2016-08-24 2020-09-25 Аркьюл, Инк. AMINOPYRROLOPYRIMIDINONE COMPOUNDS AND METHODS FOR THEIR APPLICATION
CN108530464B (en) * 2017-03-02 2020-10-27 深圳海王医药科技研究院有限公司 Multi-target kinase inhibitor
CN113874015A (en) 2018-12-21 2021-12-31 细胞基因公司 Thienopyridine inhibitors of RIPK2
CN110423218A (en) * 2019-08-09 2019-11-08 新乡双鹭药业有限公司 A kind of rich preparation method for impurity in Buddhist nun's synthesis of malic acid card
CN113336768B (en) * 2020-02-18 2022-08-19 深圳海王医药科技研究院有限公司 Multi-target tyrosine kinase inhibitor
CN114957136A (en) * 2021-02-24 2022-08-30 南京科默生物医药有限公司 Anti-tumor compound used as VEGFR inhibitor and application thereof
CN115215803B (en) * 2022-09-19 2022-12-30 苏州美诺医药科技有限公司 Preparation method of 4-halogenated-1- (difluoromethyl) -1H-imidazole

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184211B1 (en) 1993-11-30 2001-02-06 Methylgene Inc. Inhibition of DNA methyltransferase
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6268137B1 (en) 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
US6020318A (en) 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides
CA2291595A1 (en) 1997-05-30 1998-12-03 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
JP2001522853A (en) * 1997-11-11 2001-11-20 ファイザー・プロダクツ・インク Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US6066625A (en) 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
US6953783B1 (en) 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
KR20020007398A (en) 1999-05-03 2002-01-26 추후제출 Inhibition of histone deacetylase
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
JP2004533850A (en) 2000-03-24 2004-11-11 メチルジーン・インコーポレーテッド Inhibition of specific histone deacetylase isoforms
EP1280764B1 (en) 2000-03-24 2010-11-24 Methylgene, Inc. Inhibitors of histone deacetylase
MXPA02012034A (en) 2000-06-06 2003-04-25 Pfizer Prod Inc Thiophene derivatives useful as anticancer agents.
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
ES2318649T3 (en) * 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. PROCEDURE FOR PREPARATION OF DERIVATIVES OF 4-FENOXI QUINOLINAS.
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
DE60233736D1 (en) * 2001-06-22 2009-10-29 Kirin Pharma K K CHINOLIN DERIVATIVE AND CHINAZOLINE DERIVATIVES HARMING THE SELF-PHOSPHORYLATION OF THE HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICAL COMPOSITIONS CONTAINING THEREOF
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
CN1578663B (en) 2001-09-14 2011-05-25 梅特希尔基因公司 Inhibitors of histone deacetylase
EP1483268A2 (en) 2002-03-01 2004-12-08 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
CA2501265A1 (en) 2002-10-17 2004-04-29 Methylgene Inc. Inhibitors of histone deacetylase
CL2003002287A1 (en) 2002-11-25 2005-01-14 Wyeth Corp COMPOUNDS DERIVED FROM TIENO [3,2-b] -PIRIDINA-6-CARBONITRILOS AND TIENEO [2,3-b] -PIRIDINA-5-CARBONITRILS, PHARMACEUTICAL COMPOSITION, PROCEDURE OF PREPARATION AND INTERMEDIARY COMPOUNDS, AND THEIR USE IN THE TREATMENT OF CANCER, APOPLEJIA, OSTEOPOROSIS
MXPA06002296A (en) * 2003-08-29 2006-05-22 Pfizer Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents.
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
WO2005052872A1 (en) 2003-11-21 2005-06-09 Facil, Llc Financial transaction system and method
AU2005207946A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
JP2008506714A (en) 2004-07-16 2008-03-06 サネシス ファーマシューティカルズ， インコーポレイテッド Thienopyrimidines useful as aurora kinase inhibitors
CN101031570B (en) * 2004-07-30 2012-09-05 梅特希尔基因公司 Inhibitors of VEGF receptor and HGF receptor signaling
US7647492B2 (en) 2004-09-15 2010-01-12 Check Point Software Technologies Inc. Architecture for routing and IPSec integration
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
AU2006229343A1 (en) 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
TW200740820A (en) 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
DE102005037499A1 (en) 2005-08-09 2007-02-15 Merck Patent Gmbh pyrazole
JP2009521424A (en) * 2005-12-19 2009-06-04 メチルジーン インコーポレイテッド Histone deacetylase inhibitors for enhancing antifungal activity
TW200806675A (en) 2006-01-30 2008-02-01 Array Biopharma Inc Heterobicyclic thiophene compounds and methods of use
US20080064718A1 (en) 2006-03-22 2008-03-13 Saavedra Oscar M Inhibitors of protein tyrosine kinase activity

Also Published As

Publication number Publication date
EP1957498B1 (en) 2017-02-15
NZ564283A (en) 2011-07-29
EP1957498A2 (en) 2008-08-20
BRPI0610322B1 (en) 2020-12-01
CN101796055B (en) 2013-09-04
WO2008041053A2 (en) 2008-04-10
US8329726B2 (en) 2012-12-11
BRPI0610322A2 (en) 2010-06-15
AU2006343808A1 (en) 2008-04-10
US20070004675A1 (en) 2007-01-04
WO2008041053A3 (en) 2009-12-23
JP5148499B2 (en) 2013-02-20
EP1957498A4 (en) 2010-10-27
US8093264B2 (en) 2012-01-10
AU2006343808B2 (en) 2012-03-29
KR20080059112A (en) 2008-06-26
IL187484A0 (en) 2011-08-01
IL187484A (en) 2014-04-30
CA2611370A1 (en) 2006-11-20
JP2009504804A (en) 2009-02-05
ES2623221T3 (en) 2017-07-10
KR101378716B1 (en) 2014-04-10
MX2007014616A (en) 2009-08-12
US20120083482A1 (en) 2012-04-05
CN101796055A (en) 2010-08-04
CA2611370C (en) 2014-11-25

Similar Documents

Publication Publication Date Title
BRPI0610322B8 (en) vegf receptor and hgf receptor signaling inhibitors and pharmaceutical composition
BRPI0513982A (en) vegf receptor and hgf receptor signaling inhibitors
TN2009000255A1 (en) Quinazolines for pdk1 inhibition
BR112013011441A2 (en) compound, pharmaceutical composition, and use of a compound
CL2008003798A1 (en) Compounds derived from substituted aromatic heterobicycles, py3 kinase inhibitors; pharmaceutical composition; Useful in the treatment of cancer, melanomas, glioblastomas, among other diseases.
BRPI0710521A2 (en) quinazines for pdk1 inhibition
ECSP088804A (en) ANTAGONISTS OF THE AMIDA PIRIDIL OF THE TYPE T CALCIUM CHANNELS
BR112012007747A2 (en) HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS, THEIR PHARMACEUTICAL COMPOSITION AND THEIR USES
BRPI0615097A2 (en) agents for preventing and treating disorders involving ryr receptor modulation
EA200702339A1 (en) SUBSTITUTED AMIDA DERIVATIVES AS AN INHIBITOR PROTEINKINASE INHIBITORS
EA200970337A1 (en) SODIUM-GLUCOSE 2 COPHANTER OF INHIBITORS AND METHODS OF THEIR APPLICATION
EA200901032A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
ECSP10010035A (en) HETEROCYCLIC AMIDAS AND ITS METHODS OF USE
EA201200323A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
EA200900798A1 (en) INDOL-4-ILPYRIMIDINYL-2-ILAMINE DERIVATIVES AND THEIR APPLICATION AS INHIBITORS OF CYCLIN-DEPENDENT KINASE
WO2007054831A3 (en) Inhibitors of vegf receptor and hgf receptor signaling
BR112013004368A2 (en) compounds having the general formula (i) and pharmaceutical composition
CL2008003339A1 (en) Compounds derived from pyrimidin-2 (1h) -one, inhibitors of 11b-hydroxysteroid dehydrogenase 1; Pharmaceutical composition, useful for the treatment of diseases such as obesity, hypertension and hyperlipidemia.
EA200901166A1 (en) CONNECTIONS AND COMPOSITIONS AS GPR 119 ACTIVITY MODULATORS
DOP2012000006A (en) GPR119 AGONIST
DOP2007000053A (en) TETRAHYDROPIRIDOTIENOPIRIMIDINA COMPOUNDS AND METHODS FOR USE
CL2008000021A1 (en) Compounds derived from 2,4-dianilinopyrimidines, protein kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment or prevention of inflammatory diseases, diabetes, and cancer.
BRPI0606322A2 (en) intravenous formulations of pde-5 inhibitors
MX2009003981A (en) Calcium receptor modulating agents.
BRPI0806789B8 (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and, use of a compound or a pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: APRESENTE O DEPOSITANTE COPIA DA FOLHA DE ROSTO DA PUBLICACAO INTERNACIONAL DO PEDIDO, CONFORME O DISPOSTO NO ITEM 9.3 DO AN NO 128/1997.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF